Score Breakdown
Trash.
Biohaven is a high-risk pre-revenue biotech that has suffered multiple pipeline failures (opakalim MDD/BD, taldefgrobep SMA, troriluzole CRL) and now pins its future on novel degrader technology (BHV-1300, BHV-1400). While early clinical signals for BHV-1300 in Graves' disease are genuinely exciting, the investment case is severely impaired by: (1) toxic Oberland debt that captures up to 80% of future net sales and can trigger insolvency on a going-concern opinion, (2) relentless dilution (~19% annually) with share count doubling from 60M to 120M+ in three years, (3) 6-month cash runway requiring continual capital raises, (4) $4B+ in contingent milestone obligations, and (5) 24.5% short interest reflecting broad skepticism. At $10.46/share with ~$1.1B market cap and zero revenue, the stock prices in near-perfect execution on remaining programs while the Oberland structure ensures equity holders capture only residual value. This is a binary outcome where the 'house' has structural priority over common equity.
Negative cash flow. Can't value it.
Major red flags in SEC filings.
Shares melting fast.
Neutral.
Clock is ticking.
Heavy bearish bets.
Below average.
🐻 Why Bears Hate It
The short thesis is driven by a string of high-profile clinical and regulatory setbacks: opakalim (BHV-7000) failed its Phase 2 primary endpoints in both Major Depressive Disorder and Bipolar Disorder in late 2025, and taldefgrobep alfa missed its primary endpoint in Spinal Muscular Atrophy. Furthermore, the FDA issued a Complete Response Letter (CRL) for troriluzole in spinocerebellar ataxia, significantly delaying a key potential revenue stream and forcing the company into a cash-preservation pivot. (Sources: Reuters, Stock Titan)
🔍 What's In The SEC Filings
Biohaven is caught in a cycle of extreme share dilution to fund operations while facing significant litigation and a predatory debt structure that risks immediate acceleration.
Hair-trigger debt acceleration covenant tied to audit opinions.
“In the event that... the Company's audited financial statements... are subject to any qualification, emphasis of matter or statement as to 'going concern'... the Purchasers could have the right to... accelerating payment of outstanding amounts.”
The Note Purchase Agreement (NPA) treats a standard 'going concern' audit warning—common for pre-revenue biotechs—as a breach of covenant, allowing lenders to demand immediate repayment of $250 million plus premiums.
Aggressive At-The-Market (ATM) share issuance program.
“During the three months ended March 31, 2026, the Company sold and issued 17,164,940 common shares under the Equity Distribution Agreement.”
The company issued over 17 million shares in a single quarter, diluting existing shareholders by approximately 13% in just 90 days to fund a $150 million quarterly burn.
Class action lawsuit alleging securities fraud regarding lead assets.
“contending that Biohaven and the officer defendants violated Section 10(b)... based on alleged misstatements or omissions... concerning... clinical data supporting troriluzole... and opakalim’s efficacy.”
A lawsuit in the District of Connecticut alleges management misled investors about the clinical prospects of the company's most valuable pipeline assets, creating significant liability and reputational risk.
Extreme burn rate relative to cash reserves.
“The Company has incurred recurring losses since its inception and expects to continue to generate operating losses for the foreseeable future.”
With a net loss of $130.5M and operating cash use of $149.9M in Q1, the current cash position of $273M provides less than two quarters of runway without further capital raises.
Intrinsic value is severely impaired by the 'Call/Put Option' premiums in the NPA, where lenders could demand up to 225% of the funded amount, effectively siphoning future drug success proceeds away from common shareholders.
CEO maintains a conflict of interest as a co-inventor of Yale patents licensed to the company, entitling him to personal royalty cuts from payments made by the company he leads.
At the current burn rate, this company will need to raise money or die.